Apontis Pharma AG reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 19.06 million compared to EUR 28.11 million a year ago. Net loss was EUR 3.52 million compared to net income of EUR 2.35 million a year ago.